Keyphrases
Alpha-fetoprotein
14%
Atezolizumab Plus Bevacizumab
100%
Clinical Outcomes
100%
Complete Response
42%
Cox Regression Model
14%
Extrahepatic Disease
14%
Germany
14%
Hepatocellular Carcinoma
100%
Hepatocellular Carcinoma Patients
28%
Italy
14%
Japan
14%
Lenvatinib
100%
Locoregional
14%
Multivariate Analysis
14%
Objective Response Rate
42%
Odds Ratio
14%
Overall Survival
42%
Patient Demographics
14%
Patient Subgroups
28%
Portal Vein Thrombosis
14%
Response Rate
14%
Risk of Death
14%
South Korea
14%
Medicine and Dentistry
Arm
42%
Atezolizumab
100%
Bevacizumab
100%
Conditioning
14%
Disease
14%
Fetoprotein
14%
Hepatocellular Carcinoma
100%
Lenvatinib
100%
Multivariate Analysis
14%
Odds Ratio
14%
Overall Survival
42%
Patient Population
14%
Portal Vein Thrombosis
14%
Proportional Hazards Model
14%
Pharmacology, Toxicology and Pharmaceutical Science
Atezolizumab
100%
Bevacizumab
100%
Disease
14%
Fetoprotein
14%
Lenvatinib
100%
Liver Cell Carcinoma
100%
Overall Survival
42%
Portal Vein Thrombosis
14%